Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.4%

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) shares were down 6.4% on Friday . The stock traded as low as $11.21 and last traded at $11.24. Approximately 166,214 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 940,320 shares. The stock had previously closed at $12.01.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on STOK shares. JPMorgan Chase & Co. lifted their target price on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 26th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Monday. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday. Wedbush boosted their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an "outperform" rating in a research note on Tuesday, March 26th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $20.57.

Stoke Therapeutics Stock Performance

The firm's 50-day simple moving average is $10.39 and its 200-day simple moving average is $6.75.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.02. The company had revenue of $2.80 million for the quarter, compared to the consensus estimate of $3.70 million. On average, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.28 EPS for the current year.

Insider Buying and Selling

In related news, CEO Edward M. Md Kaye sold 11,150 shares of the company's stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the transaction, the chief executive officer now owns 69,350 shares in the company, valued at approximately $423,035. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the company's stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the transaction, the insider now owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 11,150 shares of the company's stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the transaction, the chief executive officer now owns 69,350 shares in the company, valued at approximately $423,035. The disclosure for this sale can be found here. Insiders have sold a total of 3,622,741 shares of company stock worth $41,935,115 in the last quarter. Corporate insiders own 11.30% of the company's stock.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Dorsey & Whitney Trust CO LLC bought a new position in shares of Stoke Therapeutics during the third quarter worth $43,000. Sherbrooke Park Advisers LLC bought a new position in shares of Stoke Therapeutics during the third quarter worth $48,000. SG Americas Securities LLC bought a new stake in shares of Stoke Therapeutics in the 3rd quarter worth about $53,000. Corton Capital Inc. purchased a new stake in shares of Stoke Therapeutics in the third quarter valued at approximately $58,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Stoke Therapeutics during the 3rd quarter worth $64,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.